Evidence map›Paper›PMID 35378749›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Insights into the limited global spread of the immune evasive SARS-CoV-2 variant Mu.

Mary E Petrone, Carolina Lucas, Bridget Menasche, Mallery I Breban, Inci Yildirim, Melissa Campbell, Saad B Omer, Albert I Ko, Nathan D Grubaugh, Akiko Iwasak and 3 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mary E PetroneDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Carolina LucasDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Bridget MenascheDepartment of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.
Mallery I BrebanDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Inci YildirimDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Melissa CampbellDepartment of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA.
Saad B OmerDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Albert I KoDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Nathan D GrubaughDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Akiko IwasakDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Craig B WilenDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Chantal B F VogelsDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Joseph R FauverDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.

Funding

IMMUNOHEMATOLOGY/TRANSFUSION MEDICINE RESEARCH TRAININGT32HL007974 · NHLBI · YALE UNIVERSITY · PI JEANNE E HENDRICKSON, Diane S Krause · 2001 to 2026
$8.1M
NHLBI NIH HHS T32 HL007974
6 · The paper itself

Abstract

SARS-CoV-2 'Variants of Concern' (VOCs) continue to reshape the trajectory of the COVID-19 pandemic. However, why some VOCs, like Omicron, become globally dominant while the spread of others is limited is not fully understood. To address this question, we investigated the VOC Mu, which was first identified in Colombia in late 2020. Our study demonstrates that, although Mu is less sensitive to neutralization compared to variants that preceded it, it did not spread significantly outside of South and Central America. Additionally, we find evidence that the response to Mu was impeded by reporting delays and gaps in the global genomic surveillance system. Our findings suggest that immune evasion alone was not sufficient to outcompete highly transmissible variants that were circulating concurrently with Mu. Insights into the complex relationship between genomic and epidemiological characteristics of previous variants should inform our response to variants that are likely to emerge in the future.

Identifiers

PMID35378749
PMCPMC8978943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.